How to Evaluate the Efficacy of the Phosphodiesterase Type 5 Inhibitors
How to Evaluate the Efficacy of the Phosphodiesterase Type 5 Inhibitors
复制标题
DOI：
10.1111/j.1743-6109.2011.02611.x
复制
发表时间：
2012-01-01
影响因子：
3.5
通讯作者：
Brock, Gerald B.
中科院分区：
文献类型：
--
作者：
Jannini, Emmanuele A.;DeRogatis, Leonard R.;Brock, Gerald B.
导言。到目前为止，已经提出了几种方法来比较三种可用的磷酸二酯酶5型抑制剂(PDE5I)的有效性。在勃起功能障碍(ED)医疗领域具有专业知识的两位泌尿科医生(E.C.和G.B.B.)以及《争论》的编辑(E.A.J.)提出了对勃起功能障碍(ED)的PDE5I评估的不同观点。最流行的心理测量工具国际勃起功能指数的使用是由一位专家心理学家(L.R.D.)介绍的。主要观察指标。专家意见得到了对现有文献的批判性审查的支持。试验证明，PDE5I是非常好的药物，具有很强的作用特异性和几乎完美的耐受性。一些用于比较临床疗效的工具必须被认为是主观的(心理测量、患者的偏好、一般质量的变化或性生活)。其他一些比较客观(硬度、荷尔蒙水平和局部循环)。今后，三种PDE5指数的循证比较应植根于主观和客观两种方法。这在新的、即将到来的PDE5的药物试验设计中将是至关重要的。使用主观和客观参数的PDE5I之间的比较将允许在证据的基础上个体化将一种药物或一种剂量或剂量方案作为首选的夫妇子集。Jannini EA，DeRogatis LR，Chung E，Brock GB。如何评价磷酸二酯酶5类抑制剂的疗效。J Sex Med 2012；9：26-33。
Introduction. Several methods have been so far proposed to compare the effectiveness of the three available phosphodiesterase type 5 inhibitors (PDE5Is).Methods. Two urologists (E. C. and G. B. B.), together with the Controversy's Editor (E.A.J.), with expertise in the area of medical treatment of erectile dysfunction (ED) present the various perspectives on the evaluation of PDE5Is in ED. The use of the most popular psychometric tool, the International Index of Erectile Function, is presented by an expert psychologist (L. R. D.). Main Outcome Measures. Expert opinion supported by the critical review of the currently available literature.Results. Trials have demonstrated that the PDE5Is are excellent drugs with a great specificity of action and an almost perfect tolerance profile. Some instruments for comparison of clinical efficacy have to be considered subjective (psychometry, patient's preference, changes in quality of general, or sexual life). Some others are more objective (hardness, hormonal levels, and local circulation). An evidence-based comparison of the three PDE5Is should in the future be rooted in both subjective and objective methods. This will be of paramount importance in the drug trial design of new, forthcoming PDE5Is.Conclusions. Comparison between PDE5Is using both subjective and objective parameters will permit to individuate, on the basis of the evidence, the subset of couples where one drug, or one dose, or dose regimen, is to be considered of first choice. Jannini EA, DeRogatis LR, Chung E, and Brock GB. How to evaluate the efficacy of the phosphodiesterase type 5 inhibitors. J Sex Med 2012; 9: 26-33.